Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Enabling the transition to 3D digital pathology

Project description

3D tissue scanner for cancer diagnosis

Histopathology, the gold standard for cancer diagnosis, relies on 2D tissue slices, which can limit accuracy and, in some cases, influence treatment decisions. Although volumetric tissue analysis offers clear advantages, the field remains largely dependent on traditional 2D methods. Light-sheet fluorescence microscopy (LSFM) shows great potential for 3D imaging, but its broader application has been held back by technical challenges. In this context, the EIC-funded 3DPATH project will leverage key innovations in LSFM and data analysis developed in earlier research efforts to build a 3D tissue scanner suitable for clinical use. The aim is to enable more accurate diagnoses and significantly improve patient care. It also promises to position Europe as a leader in next-generation diagnostic technologies.

Objective

Histopathology is a century-old standard for the diagnosis of cancer and other diseases, and for the choice of personalized treatments. Despite its paramount importance for clinical practice, this method is still limited to the analysis of thin slices, presenting a 2D view of the intrinsically 3D structure of biological tissue. Current histopathology practice poses the risk of severely undersampling relevant tissue features: indeed, a growing amount of data demonstrates that traditional 2D analysis produces inconsistent and unreliable results that may have important implications in treatment choice and other clinical decisions.

Despite the compelling evidence of the clinical benefits of volumetric tissue analysis, clinical practice is still anchored to 2D imaging. A transition towards 3D inspection would be a quantum leap in the histopathology field but has been prevented hitherto because of technical limitations. Indeed, light-sheet fluorescence microscopy (LSFM) has been hailed in the last decades as a game changer in the field. However, LSFM-based solutions have profound limitations in terms of throughput, reliability and scalability that prevent their use outside specialised research labs.

In 3DPATH, we want to leverage several key innovations in LSFM and data analysis technology – developed in previous research projects – to develop a 3D tissue scanner suitable for clinical use. The success of this project will revolutionize histopathology leading to more accurate diagnosis, improving quality of care for patients all over the world, and bringing Europe at the forefront of diagnostic technologies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-TRANSITION-01

See all projects funded under this call

Coordinator

CLEPIO BIOTECH SRL
Net EU contribution
€ 1 392 208,00
Address
VIA GIUSEPPE GARIBALDI 159
50019 SESTO FIORENTINO
Italy
SME
Yes
Region
Centro (IT) Toscana Firenze
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data

Participants (1)

Partners (1)